MivInvestments Inc. has initiated an independent bullish technical trading alert for 11/20/09 on Echo Therapeutics, Inc. (OTC:ECTE.OB). Shares of the company finished the day at $1.35, up 8.15% from the opening bell on heavy buying pressure. The excitement was due to the announcement on positive results of a clinical study testing symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes. Despite the fact that there has been a recent common shares financing scheduled, companies usually take their time and let the price consolidate before engaging in these activities, thus a short-term buy could be a smart investment. Towards the end of this alert a technical analysis will also be issued.

According to the ADA, the cost of diabetes care in the United States in 2007 was more than $174 billion, including $116 billion in excess medical expenditures attributed to diabetes and

...

Enzo Biochem Inc. (NYSE:ENZ) announced today that they have favorable results of the Company’s clinical trial for the treatment of non-alcoholic steatohepatitis. The information was presented by Enzo Biochem at the annual meeting of the American Association for the Study of Liver Diseases. Currently, the causes of NASH are not well-defined due to which there is currently no medical therapy available in the market to combat NASH.

Enzo Biochem is one of the leading biopharmaceuticals companies that is into research and development, manufacturing, licensing of innovative healthcare products and technologies based on molecular biology and genetic engineering techniques. Currently, the Company has around forty thousand products that serve under molecular biology, drug discovery, and pathology research markets. Enzo’s scientists and collaborators have presented the data that showed that oral administration of EGS21 is safe and remains biologically active in the patients with insulin resistance and NASH which leads to the

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

PWRM, AMLN

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday November 2nd, 2009, are:

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.

AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection.

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for AMLN’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for

...

Orexigen Therapeutics, Inc. (NASDAQ:OREX) has announced and presented their new data from the COR diabetes trials for Contrave to expand on top line results announced in July this year. This new data shows that after completing 56 weeks of therapy, Contrave patients have lost weight significantly and improved on important markers of cardiometabolic risk. Though it was good news for investors and analysts, shares dropped a bit and showed no signs of moving upward. The new data was presented during the panel discussion at the 27th Annual Scientific Meeting of The Obesity Society.

Obese patients have a higher risk of developing cardiovascular disease and diabetes. After the Contrave trials patients demonstrated significant improvements in their waist circumference, HDL and triglycerides. Patients with Type 2 diabetes taking Contrave saw a

...

Amylin Pharmaceuticals (AMLN) reported a loss of 19 cents per share in the third quarter, which was narrower than the Zacks Consensus Estimate of a loss of 30 cents. In the prior-year period, the company had incurred a loss of 47 cents. Total revenues for the quarter were $211.2 million, down 3.3% year over year.   Revenues consisted of $192.9 million in product sales and $18.3 million in collaborative payments from partner Eli Lilly (LLY). Product sales comprised $171.1 million in sales of Byetta and $21.8 million in sales of Symlin. Byetta sales declined both on a yearly and sequential basis. The company attributed the sequential decline in Byetta sales to an increase in wholesaler stocking in the previous quarter. We believe Byetta continues to be affected by safety issues surrounding the use of the drug.   Selling, general and administrative expenses decreased to $80.1 million from ...

Early Wednesday afternoon, Merck announced that they have made a decision of research collaboration with Galapagos NV. The news about the research collaboration had positive responses from analysts and the shares of Merck went up shortly after the announcement was made. Building on the deal struck at the very beginning of the year, Merck has boosted its commitment on milestones for new atherosclerosis therapies for more than 400 million Euros. Galapagos NV was founded ten years ago as a joint venture between Crucell and Tibotec. The company has always adopted hybrid business model and have come up quickly raising funds through private placements and public offerings.

As per the strategic alliance between Merck and Galapagos for the development of new therapies for atherosclerosis, Galapagos VN will be responsible for the discovery

...

The existing alliance between Merck (MRK) and Belgian biotech company Galapagos over metabolic diseases was recently expanded to develop new therapies for atherosclerosis, or hardening of arteries due to cholesterol build-up.

Following the deal, Galapagos will be eligible to receive potential milestone payments exceeding €400 million (approx $597 million). Additionally, the company will receive royalties on commercialization of the products.

Merck and Galapagos entered into a diabetes and obesity drug alliance in January this year. Galapagos was eligible to receive an upfront payment of €1.5 million (approx $2.23 million) and potential milestone payments totaling €170 million (approx $253 million).

Earlier, in October last year, Merck decided to terminate its late-stage obesity drug taranabant after determining that the drug was effective in high doses, which in turn triggered side effects.

Merck entered into another deal with Galapagos in April 2009, under which Galapagos will be using its Silence Select target discovery platform to

...

Obesity is a leading risk factor behind many cardiovascular diseases, cancers and type 2 diabetes. According to the Centers for Disease Control and Prevention, in the past 20 years there has been a dramatic increase in obesity. Though public awareness has prompted more Americans to hit the gym and lead healthier lifestyles, calories and fat in beverages such as juices, energy and soft drinks are often overlooked, subtly contributing to weight-gain and health issues.

Celsius Holdings Inc. has developed an original drink to generate the opposite effect. The company’s Celsius® calorie burning beverage has been scientifically proven to burn approximately 100 calories per can through boosting metabolism and providing sustained energy over a three-hour period.

The company today announced increased availability of Celsius, as the product is available at approximately 1,800 SUPRERVALU stores.

“We are thrilled to be carried by SUPERVALU, a leading grocery retailer with unsurpassed recognition in the

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...